Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1661447rdf:typepubmed:Citationlld:pubmed
pubmed-article:1661447lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:1661447lifeskim:mentionsumls-concept:C0016017lld:lifeskim
pubmed-article:1661447lifeskim:mentionsumls-concept:C0019134lld:lifeskim
pubmed-article:1661447lifeskim:mentionsumls-concept:C0030190lld:lifeskim
pubmed-article:1661447lifeskim:mentionsumls-concept:C0442805lld:lifeskim
pubmed-article:1661447lifeskim:mentionsumls-concept:C0392747lld:lifeskim
pubmed-article:1661447lifeskim:mentionsumls-concept:C1442989lld:lifeskim
pubmed-article:1661447lifeskim:mentionsumls-concept:C0205263lld:lifeskim
pubmed-article:1661447lifeskim:mentionsumls-concept:C2603343lld:lifeskim
pubmed-article:1661447lifeskim:mentionsumls-concept:C0439228lld:lifeskim
pubmed-article:1661447lifeskim:mentionsumls-concept:C1554963lld:lifeskim
pubmed-article:1661447lifeskim:mentionsumls-concept:C0521115lld:lifeskim
pubmed-article:1661447lifeskim:mentionsumls-concept:C2348867lld:lifeskim
pubmed-article:1661447pubmed:issue5lld:pubmed
pubmed-article:1661447pubmed:dateCreated1992-1-27lld:pubmed
pubmed-article:1661447pubmed:abstractTextThe relationship between heparin and fibrinolysis is strongly suggested. We have studied the influence on fibrinolysis of standard heparin (SH), Calciparin and low molecular weight heparin (LMWH), Fraxiparin, given preventively in an elderly population. Patients were randomized into two groups (SH, LMWH). We investigated fibrinolytic parameters (ECLT, t-PA antigen, PAI-1 activity and antigen, t-PA/PAI-1 complexes) before treatment (D0) and at D30 and D60, before and after venous occlusion (VO). Values at D0, D30 and D60 were compared within each group. A significant and marked increase in t-PA and t-PA/PAI-1 complexes at D30 and D60 before and after VO was noted only in the SH group. The mechanism and clinical relevance of this increase remains to be established.lld:pubmed
pubmed-article:1661447pubmed:languageenglld:pubmed
pubmed-article:1661447pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1661447pubmed:citationSubsetIMlld:pubmed
pubmed-article:1661447pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1661447pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1661447pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1661447pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1661447pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1661447pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1661447pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1661447pubmed:statusMEDLINElld:pubmed
pubmed-article:1661447pubmed:monthSeplld:pubmed
pubmed-article:1661447pubmed:issn0049-3848lld:pubmed
pubmed-article:1661447pubmed:authorpubmed-author:BoisseauM RMRlld:pubmed
pubmed-article:1661447pubmed:authorpubmed-author:MancietGGlld:pubmed
pubmed-article:1661447pubmed:authorpubmed-author:VergnesCClld:pubmed
pubmed-article:1661447pubmed:authorpubmed-author:LacombeFFlld:pubmed
pubmed-article:1661447pubmed:authorpubmed-author:RoudautM FMFlld:pubmed
pubmed-article:1661447pubmed:authorpubmed-author:BourdenxVVlld:pubmed
pubmed-article:1661447pubmed:issnTypePrintlld:pubmed
pubmed-article:1661447pubmed:day1lld:pubmed
pubmed-article:1661447pubmed:volume63lld:pubmed
pubmed-article:1661447pubmed:ownerNLMlld:pubmed
pubmed-article:1661447pubmed:authorsCompleteYlld:pubmed
pubmed-article:1661447pubmed:pagination521-30lld:pubmed
pubmed-article:1661447pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:1661447pubmed:meshHeadingpubmed-meshheading:1661447-...lld:pubmed
pubmed-article:1661447pubmed:meshHeadingpubmed-meshheading:1661447-...lld:pubmed
pubmed-article:1661447pubmed:meshHeadingpubmed-meshheading:1661447-...lld:pubmed
pubmed-article:1661447pubmed:meshHeadingpubmed-meshheading:1661447-...lld:pubmed
pubmed-article:1661447pubmed:meshHeadingpubmed-meshheading:1661447-...lld:pubmed
pubmed-article:1661447pubmed:meshHeadingpubmed-meshheading:1661447-...lld:pubmed
pubmed-article:1661447pubmed:meshHeadingpubmed-meshheading:1661447-...lld:pubmed
pubmed-article:1661447pubmed:meshHeadingpubmed-meshheading:1661447-...lld:pubmed
pubmed-article:1661447pubmed:meshHeadingpubmed-meshheading:1661447-...lld:pubmed
pubmed-article:1661447pubmed:meshHeadingpubmed-meshheading:1661447-...lld:pubmed
pubmed-article:1661447pubmed:meshHeadingpubmed-meshheading:1661447-...lld:pubmed
pubmed-article:1661447pubmed:meshHeadingpubmed-meshheading:1661447-...lld:pubmed
pubmed-article:1661447pubmed:meshHeadingpubmed-meshheading:1661447-...lld:pubmed
pubmed-article:1661447pubmed:meshHeadingpubmed-meshheading:1661447-...lld:pubmed
pubmed-article:1661447pubmed:meshHeadingpubmed-meshheading:1661447-...lld:pubmed
pubmed-article:1661447pubmed:year1991lld:pubmed
pubmed-article:1661447pubmed:articleTitleStandard heparin but not LMW heparin induces a concomitant increase of t-PA and PAI-1 without modification of global fibrinolysis: study after 60 days treatment.lld:pubmed
pubmed-article:1661447pubmed:affiliationLaboratoire d'Hémobiologie, Hopital Cardiologique, Hôpital Xavier Arnozan, Pessac, France.lld:pubmed
pubmed-article:1661447pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1661447pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:1661447pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:1661447pubmed:publicationTypeRandomized Controlled Triallld:pubmed